Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Two brief valid measures of therapeutic alliance in counseling for tobacco dependence.

Warlick C, Richter KP, Catley D, Gajewski BJ, Martin LE, Mussulman LM.

J Subst Abuse Treat. 2018 Mar;86:60-64. doi: 10.1016/j.jsat.2017.12.010. Epub 2017 Dec 29.

PMID:
29415852
2.

Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.

Karanevich AG, Statland JM, Gajewski BJ, He J.

BMC Med Res Methodol. 2018 Feb 6;18(1):19. doi: 10.1186/s12874-018-0479-9.

3.

Changing the default for tobacco-cessation treatment in an inpatient setting: study protocol of a randomized controlled trial.

Faseru B, Ellerbeck EF, Catley D, Gajewski BJ, Scheuermann TS, Shireman TI, Mussulman LM, Nazir N, Bush T, Richter KP.

Trials. 2017 Aug 14;18(1):379. doi: 10.1186/s13063-017-2119-9.

4.

Comparison of Dichotomized and Distributional Approaches in Rare Event Clinical Trial Design: a Fixed Bayesian Design.

Lei Y, Carlson S, Yelland LN, Makrides M, Gibson R, Gajewski BJ.

J Appl Stat. 2017;44(8):1466-1478. doi: 10.1080/02664763.2016.1214244. Epub 2016 Aug 12.

5.

Personalized Medicine Enrichment Design for DHA Supplementation Clinical Trial.

Lei Y, Mayo MS, Carlson SE, Gajewski BJ.

Contemp Clin Trials Commun. 2017 Mar;5:116-122. doi: 10.1016/j.conctc.2017.01.002. Epub 2017 Jan 27.

6.

Assessment of DHA on reducing early preterm birth: the ADORE randomized controlled trial protocol.

Carlson SE, Gajewski BJ, Valentine CJ, Rogers LK, Weiner CP, DeFranco EA, Buhimschi CS.

BMC Pregnancy Childbirth. 2017 Feb 13;17(1):62. doi: 10.1186/s12884-017-1244-5.

7.

Commitment and capacity for providing evidence-based tobacco treatment in US drug treatment facilities.

Richter KP, Hunt JJ, Cupertino AP, Gajewski BJ, Jiang Y, Marquis J, Friedmann PD.

Subst Abus. 2017 Jan-Mar;38(1):35-39. doi: 10.1080/08897077.2016.1265039. Epub 2016 Nov 29.

8.

Prenatal DHA supplementation and infant attention.

Colombo J, Gustafson KM, Gajewski BJ, Shaddy DJ, Kerling EH, Thodosoff JM, Doty T, Brez CC, Carlson SE.

Pediatr Res. 2016 Nov;80(5):656-662. doi: 10.1038/pr.2016.134. Epub 2016 Jun 30.

9.

A novel method for expediting the development of patient-reported outcome measures and an evaluation across several populations.

Garrard L, Price LR, Bott MJ, Gajewski BJ.

Appl Psychol Meas. 2016 Oct;40(7):455-468. Epub 2016 Jun 14.

10.

Predicting the effect of maternal docosahexaenoic acid (DHA) supplementation to reduce early preterm birth in Australia and the United States using results of within country randomized controlled trials.

Yelland LN, Gajewski BJ, Colombo J, Gibson RA, Makrides M, Carlson SE.

Prostaglandins Leukot Essent Fatty Acids. 2016 Sep;112:44-9. doi: 10.1016/j.plefa.2016.08.007. Epub 2016 Aug 17.

11.

A pressure ulcer and fall rate quality composite index for acute care units: A measure development study.

Boyle DK, Jayawardhana A, Burman ME, Dunton NE, Staggs VS, Bergquist-Beringer S, Gajewski BJ.

Int J Nurs Stud. 2016 Nov;63:73-81. doi: 10.1016/j.ijnurstu.2016.08.020. Epub 2016 Sep 1.

12.

A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.

Brown AR, Gajewski BJ, Aaronson LS, Mudaranthakam DP, Hunt SL, Berry SM, Quintana M, Pasnoor M, Dimachkie MM, Jawdat O, Herbelin L, Barohn RJ.

Trials. 2016 Aug 31;17(1):428. doi: 10.1186/s13063-016-1544-5.

13.

Docosahexaenoic acid supplementation (DHA) and the return on investment for pregnancy outcomes.

Shireman TI, Kerling EH, Gajewski BJ, Colombo J, Carlson SE.

Prostaglandins Leukot Essent Fatty Acids. 2016 Aug;111:8-10. doi: 10.1016/j.plefa.2016.05.008. Epub 2016 May 13.

14.

Bayesian accrual prediction for interim review of clinical studies: open source R package and smartphone application.

Jiang Y, Guarino P, Ma S, Simon S, Mayo MS, Raghavan R, Gajewski BJ.

Trials. 2016 Jul 22;17(1):336. doi: 10.1186/s13063-016-1457-3.

15.

Commensurate Priors on a Finite Mixture Model for Incorporating Repository Data in Clinical Trials.

Gajewski BJ, Reese CS, Colombo J, Carlson SE.

Stat Biopharm Res. 2016;8(2):151-160. Epub 2016 Jun 2.

16.

Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling.

Gajewski BJ, Berry SM, Barsan WG, Silbergleit R, Meurer WJ, Martin R, Rockswold GL.

Pharm Stat. 2016 Sep;15(5):396-404. doi: 10.1002/pst.1755. Epub 2016 Jun 15.

17.

A novel evaluation of optimality for randomized controlled trials.

Wick J, Berry SM, Yeh HW, Choi W, Pacheco CM, Daley C, Gajewski BJ.

J Biopharm Stat. 2017;27(4):659-672. doi: 10.1080/10543406.2016.1198367. Epub 2016 Jun 13.

18.

Reducing Iron Deficiency in 18-36-months-old US Children: Is the Solution Less Calcium?

Kerling EH, Souther LM, Gajewski BJ, Sullivan DK, Georgieff MK, Carlson SE.

Matern Child Health J. 2016 Sep;20(9):1798-803. doi: 10.1007/s10995-016-1982-4.

PMID:
26987860
19.

A novel method for expediting the development of patient-reported outcome measures and an evaluation of its performance via simulation.

Garrard L, Price LR, Bott MJ, Gajewski BJ.

BMC Med Res Methodol. 2015 Sep 29;15:77. doi: 10.1186/s12874-015-0071-5.

20.

Bayesian and frequentist approaches to assessing reliability and precision of health-care provider quality measures.

Staggs VS, Gajewski BJ.

Stat Methods Med Res. 2017 Jun;26(3):1341-1349. doi: 10.1177/0962280215577410. Epub 2015 Mar 17.

PMID:
25788482

Supplemental Content

Loading ...
Support Center